GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MeiraGTx Holdings PLC (NAS:MGTX) » Definitions » Earnings per Share (Diluted)

MeiraGTx Holdings (MeiraGTx Holdings) Earnings per Share (Diluted) : $-1.17 (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is MeiraGTx Holdings Earnings per Share (Diluted)?

MeiraGTx Holdings's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.32. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.17.

MeiraGTx Holdings's EPS (Basic) for the three months ended in Mar. 2024 was $-0.32. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.17.

MeiraGTx Holdings's EPS without NRI for the three months ended in Mar. 2024 was $-0.77. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.37.

During the past 3 years, the average EPS without NRIGrowth Rate was -17.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 3.00% per year.

During the past 8 years, MeiraGTx Holdings's highest 3-Year average EPS without NRI Growth Rate was 26.70% per year. The lowest was -19.40% per year. And the median was -15.20% per year.


MeiraGTx Holdings Earnings per Share (Diluted) Historical Data

The historical data trend for MeiraGTx Holdings's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MeiraGTx Holdings Earnings per Share (Diluted) Chart

MeiraGTx Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial -1.65 -1.54 -1.80 -2.87 -1.49

MeiraGTx Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.62 -0.53 -0.74 0.42 -0.32

Competitive Comparison of MeiraGTx Holdings's Earnings per Share (Diluted)

For the Biotechnology subindustry, MeiraGTx Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MeiraGTx Holdings's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where MeiraGTx Holdings's PE Ratio falls into.



MeiraGTx Holdings Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

MeiraGTx Holdings's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-84.027-0)/56.487
=-1.49

MeiraGTx Holdings's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-20.442-0)/64.066
=-0.32

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


MeiraGTx Holdings  (NAS:MGTX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


MeiraGTx Holdings Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of MeiraGTx Holdings's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


MeiraGTx Holdings (MeiraGTx Holdings) Business Description

Traded in Other Exchanges
Address
450 East 29th Street, 14th Floor, New York, NY, USA, 10016
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Executives
Perceptive Life Sciences Master Fund Ltd director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson 10 percent owner ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Robert K Zeldin officer: Chief Medical Officer C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Robert J Wollin officer: General Counsel and Secretary 450 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Debra Yu director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Alexandria Forbes director, officer: President & CEO C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Richard Giroux officer: Chief Operating Officer C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Stuart Naylor director, officer: Chief Dev. Officer C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Joel S Marcus director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Thomas E Shenk director C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Nicole Seligman director C/O VIACOM INC., 1515 BROADWAY, NEW YORK NY 10036
Perceptive Advisors Llc director, 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ellen Hukkelhoven director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

MeiraGTx Holdings (MeiraGTx Holdings) Headlines

From GuruFocus